Shanghai PINE&POWER Biotech

Shanghai PINE&POWER Biotech focuses on innovative biotechnology solutions to improve operational efficiencies across various sectors, aiming to enhance productivity and collaboration in project management. Shanghai PINE&POWER Biotech, founded in 2002 in Shanghai, China, specializes in biotechnology solutions. The company raised USD 11. 00 mn in its Series A funding round on September 20, 2017, with investments from Jiuzhou Venture and Qiming Venture Partners.

The total amount raised by the company is USD 11. 00 mn. The CEO, Hongbing He, leads the firm with a vision grounded in advanced technological applications within the biotechnology landscape. The company specializes in providing technology solutions designed to enhance operational efficiency and drive innovation across various industries.

Its flagship product, a robust software platform released in early 2021, streamlines project management and collaboration, integrating advanced analytics and AI capabilities for real-time data tracking and resource allocation. This platform serves mid-sized enterprises primarily in North America and Europe, with project managers and team leaders in construction, IT, and marketing as main end users. Additionally, the company offers tailored consulting services to help clients implement and maximize their software use, delivering comprehensive technological and strategic solutions. The company generates revenue through a subscription-based model with tiered pricing plans depending on user count and feature access.

Clients typically engage with annual contracts, selecting packages that range from basic project management tools to advanced analytics capabilities. Transactions often involve clients subscribing to premium plans for full feature access, including dedicated support and regular updates. The firm also earns additional revenue through consulting services, charged separately based on engagement scope, thus diversifying income streams while providing extensive client support. Shanghai PINE&POWER Biotech is focused on launching new products and expanding into new markets.

The firm plans to enhance its existing software offerings with new features aimed at improving user experience and functionality, with a targeted rollout in 2023. In addition to product development, there are plans to enter the Asian and European markets by 2025. The recent funding, raised during the Series A round, will support these initiatives, allowing the company to invest in product development and market entry strategies, ultimately aiming to strengthen its position within the biotechnology sector.